Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | Blank 4 | Frequency | Blank 5 | Frequency | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | as a part of the oncology patient enrollment network open registration process the treating institution s identity is provided in order to ensure that the current | 31 | 365 | 48 | date | 48 | institutional review board approval for this | 48 | has been entered in the system | 45 |
| 2 | 9 | as a part of the open registration process the treating institution s identity is provided in order to ensure that the current | 6 | 14 or 21 | 4 | 5 | 7 | entry | 3 | ||
| 3 | 2 | as part of the oncology patient enrollment network open registration process the treating institution s identity is provided in order to ensure that the current | 4 | the last 30 | 3 | with a drug that has not received regmcLatory approval for any indication at the time | 3 | the initial dose of | 3 | drug for a nonmyelosuppressive or myelosuppressive agent respectively . | 2 |
| 4 | 52 | have received treatment with a drug that has not received regmcLatory approval for any indication | 4 | 14 | 1 | prior to randomization | 2 | the first dose of | 1 | drug for a nonmyelosuppressive or myelosuppressive agent respectively | 2 |
| 5 | 51 | have received treatment | 3 | the last 28 | 1 | prior to study entry with any drug that has not received regmcLatory approval for an indication at the time | 1 | NA | had been entered in the system | 1 | |
| 6 | 28 | regmcLatory criteria as a part of the oncology patient enrollment network open registration process the treating institution s identity is provided in order to ensure that the current | 2 | 28 | 1 | NA | NA | has been entered into the system | 1 | ||
| 7 | 50 | treatment | 2 | 21 | 1 | NA | NA | has been entered into the database | 1 | ||
| 8 | 4 | as part of the open registration process the treating institution s identity is provided in order to ensure that the current | 1 | NA | NA | NA | drug for a nonmyelosuppressive agent or 21 days of the first dose of study drug for a myelosuppressive agent | 1 | |||
| 9 | 6 | step 2 randomization as a part of the open registration process the treating institution s identity is provided in order to ensure that the current | 1 | NA | NA | NA | entry or used an investigational device within 4 weeks of the first dose of treatment | 1 | |||
| 10 | 7 | step 3 crossover registration optional as a part of the open registration process the treating institution s identity is provided in order to ensure that the current | 1 | NA | NA | NA | treatment with dkn 01 | 1 | |||
| 11 | 16 | all patients as a part of the oncology patient enrollment network open registration process the treating institution s identity is provided in order to ensure that the current | 1 | NA | NA | NA | drug with an experimental agent for noncancer indications that has not received regmcLatory approval for any indication . | 1 | |||
| 12 | 44 | at the time of patient registration the treating institution s name and identification id number must be provided to the data operations center in seattle in order to ensure that the current | 1 | NA | NA | NA | NA | ||||
| 13 | 49 | received another investigational agent defined as any agent / device that has not received regmcLatory approval for any indication | 1 | NA | NA | NA | NA | ||||
| 14 | 58 | 1 | NA | NA | NA | NA |